Cabaletta Confident It Will Put Philly on the Biotech Map
Company IPO raised $75 million, which will help fund first clinical trialRelated Stocks: CABA,.....»»
Cabaletta Bio prices IPO at $11 a share, below $14 to $16 price range
Cabaletta Bio Inc. said Friday it priced its initial public offering at $11 a share, selling 6.8 million shares to raise $74.8 million. The clinical-stage biotech priced the deal well below its price rang.....»»
Alphabet CEO "Very, Very Confident" That It Won"t Be "Costly To Serve" Search Experience With Generative Answers
Alphabet Inc. CEO Sundar Pichai confidently addressed th.....»»
Life sciences tools maker to pare 10% of workforce in latest biotech industry cuts
The company over the past two years has tried to pull good-but-underperforming products under one umbrella and in January completed a merger with SomaLogic......»»
Jennifer Doudna co-founded Peninsula biotech lands CRISPR gene-editing pact with Regeneron
The deal, which could pay the Peninsula company a $100 million upfront and up to $370 million per target, is the third aimed at assembling CRISPR's components in the body......»»
Petri Dish: Vertex scales cell manufacturing; German biotech enters Mass.
Moving to Massachuse.....»»
Brookings takes closer look at Pitt BioForge, Krystal Biotech success in Pittsburgh
The think tank highlighted the Pittsburgh region's efforts to grow biotech and bioscience......»»
Philadelphia suburb lands on Money magazine"s 2024 list of "Best Places to Live"
The magazine touted the town as a "walkable Philly 'burb with parks, restaurants and good schools.".....»»
Supreme Court will not hear D.C. biotech"s patent infringement appeal
As a result, the company stands to lose revenue related to one of the three drugs it has on the market......»»
Five things: Rapid7"s CEO pay, biotech layoffs and big deals, Hadestown, who"s on "Fire" and having a best friend at work
Good morning, Boston. Passover begins today. Here are the five things you need to know in Boston business news to start your Tuesday. The value of last year's total compensation package for Rapid7 CEO Corey Thomas came in at about a third of th.....»»
Should You Be Confident in Biogen (BIIB)?
Patient Capital Management, a value investing firm, released its “Patient Capital Opportunity Equity Strategy” first quarter 2024 investor letter. A copy of the same can be downloaded here. During the quarter the strategy ret.....»»
Former CHOP CEO and Spark co-founder to lead new biotech startup launched with $54M in funding
Altschuler said the $54 million in funding "will put rocket boosters under Corner's pioneering work.".....»»
After Karuna"s acquisition, former CEO lands new gig at Cambridge biotech
Bill Meury is now leading a clinical-stage Cambridge company developing treatments for cardiovascular diseases......»»
Bitcoin is still headed to $150,000 by year-end despite the recent pullback, Standard Chartered says
Standard Chartered is still confident that the world's largest crypto could more than double in price through the rest of 2024. Business Insider Bitcoin is still on track to more than double its price by the end of the .....»»
Case Western Reserve launches startup incubator in Cleveland Innovation District
Case Western Reserve University has redeveloped the former BioEnterprise Inc. building in University Circle as a startup incubator for early-stage businesses in the biotech, health tech and engineering fields......»»
Spark co-founder, Harvard professor launch Watertown biotech with $54M
The Watertown startup has an ambitious goal of developing vaccines that provide lifelong protection from cancer and infectious diseases......»»
Missouri initiative campaigns confident of achieving signature goals
Three initiative campaigns say they are on track to submit signatures that would put measures to legalize abortion and sports wagering, and to increase the minimum wage, on Missouri’s ballot this year. Campaign finance reports filed this week show m.....»»
Wall Street Experts Dismiss Rate Cut Fears, Middle East Tensions, Predict Bull Market"s Continuation
Despite recent concerns, Wall Street veterans are confident that the bull market will persist, citing a robust U.S. economy and the potential of artificial intelligence (AI) as key drivers. read more.....»»
Adaptive Biotechnologies names new CFO, restructures business lines
The Seattle-based biotech is looking to make its two internal businesses more independent from each other......»»
The Biotech Rebound Is Just Beginning
Health care and biotech stocks are poised to take off in the years to come, thanks to new technologies and medicines......»»
RTP firm sells more assets after struggling to raise money
The cash-strapped biotech is selling more assets after last year telling state officials it may have to lay off its entire staff......»»